SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (9525)2/1/2003 6:11:13 PM
From: Icebrg  Read Replies (1) | Respond to of 9719
 
V1

Not that one man's opinion matters very much - even if he happens to be the lead investigator. But I would still like to suggest that you listen to the ASH presentation by Dr. Kenneth Anderson. In his mind even Miljenko's 99 % might look as being on the cautious side.

For the audio and slides presentation, you can visit

phx.corporate-ir.net

I think it is time well spent (it is interesting).

Erik



To: Vector1 who wrote (9525)2/1/2003 11:08:54 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 9719
 
<< I wouldn't give a 99% likelihood of the FDA approving anything much less a drug without a controlled trial without any insight into the rigor of the trial or insight into the quality of the data.>>

V1, did you investigated Velcade at all? Or, you are just talking talk?

With all due respect, I think it is later one.

Miljenko


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News